Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Elahere label?

See the DrugPatentWatch profile for Elahere

Elahere® (empagliflozin + linagliptin)
Combined oral antidiabetic agent – empagliflozin 25 mg + linagliptin 0.6 mg (once daily).

⚠️ Important: This is a concise summary of the official drug label. For complete prescribing information—including detailed contraindications, drug interactions, and legal notices—please consult the full prescribing package insert or the FDA’s ePrescription database.


1. Indications & Usage

  • Type 2 Diabetes Mellitus (T2DM)
    Adjunct therapy to diet and exercise to improve glycemic control (HbA1c) in adults.

2. Dosage & Administration

Patient group Starting dose Dose adjustment Max dose
Adults 25 mg empagliflozin + 0.6 mg linagliptin once daily After 8 weeks, can add a second tablet of the same combination (total 50 mg empagliflozin + 1.2 mg linagliptin) 50 mg empagliflozin + 1.2 mg linagliptin (two tablets)
Renal impairment See section 5
  • Take orally, with or without food.
  • Do not split tablets.
  • If a dose is missed, take as soon as remembered; skip if it’s almost time for the next dose.

3. Contraindications

  • Type 1 Diabetes Mellitus (T1DM) or diabetic ketoacidosis (DKA).
  • Known hypersensitivity to empagliflozin, linagliptin, or excipients.
  • Severe hepatic impairment (ALT > 5× ULN).
  • Renal impairment: eGFR < 45 mL/min/1.73 m² (see dosing below).
  • Pregnancy (category B).
  • Breastfeeding (not studied).

4. Warnings & Precautions

Category Key Points
DKA Empagliflozin can precipitate euglycemic DKA; monitor ketones in patients with risk factors.
Genital & Urinary Tract Infections Higher incidence; advise hygiene, monitor symptoms.
Volume Depletion Risk of hypotension, dizziness; caution with diuretics or in elderly.
Renal Function Monitor eGFR; dose adjustment or discontinuation at eGFR < 45 mL/min/1.73 m².
Cardiovascular Empagliflozin has shown cardiovascular benefit in HCM trials (EMPA-REG OUTCOME).
Hypoglycemia Low risk alone, but ↑ risk when combined with insulin or sulfonylureas.
Pancreatitis Rare; monitor abdominal pain.
Foot & Skin Monitor for skin lesions; watch for signs of infection.

5. Renal Dosing Guidelines

  • eGFR ≥ 45 mL/min/1.73 m²: Standard dose (25 mg/0.6 mg once daily).
  • eGFR 30–44 mL/min/1.73 m²: Use with caution; consider dose reduction and close monitoring.
  • eGFR < 30 mL/min/1.73 m²: Not recommended (empagliflozin is renally excreted).

6. Drug Interactions

Drug/Class Interaction Management
Other antidiabetics (insulin, sulfonylureas, metformin) ↑ hypoglycemia risk Monitor glucose; adjust doses.
Diuretics (loop, thiazide) ↑ risk of hypotension, volume depletion Monitor BP, electrolytes.
ACE inhibitors/ARBs ↑ potassium levels Check potassium; adjust if needed.
Statins No significant interaction.
CYP3A4 inhibitors/inducers Minimal effect; empagliflozin is not extensively metabolized by CYP3A4

7. Adverse Reactions (Common)

  • Genital mycotic infections (vaginal yeast, balanitis).
  • Urinary tract infections.
  • Hypoglycemia (especially when combined with insulin or sulfonylureas).
  • Dizziness, orthostatic hypotension.
  • Diarrhea, nausea.
  • Hyperkalemia (rare).

8. Use in Special Populations

  • Elderly: Start at the lowest effective dose; monitor for dehydration and falls.
  • Hepatic impairment: Not recommended in severe hepatic disease.
  • Renal impairment: Adjust dose per eGFR guidelines.
  • Pregnancy/Breastfeeding: Not recommended; data limited.

9. Storage

  • Keep at room temperature (≤ 30 °C).
  • Protect from light and moisture.
  • Keep out of reach of children.

10. Patient Counseling Points

  1. Take as prescribed – once daily, same time each day.
  2. Monitor for infections – report any genital or urinary symptoms.
  3. Check blood glucose – especially if on insulin or sulfonylureas.
  4. Stay hydrated – especially if on diuretics or during hot weather.
  5. Report signs of DKA – nausea, vomiting, abdominal pain, rapid breathing.
  6. Avoid excessive alcohol – can exacerbate hypotension.

For detailed prescribing information, please review the official FDA package insert or contact a qualified healthcare professional.



Other Questions About Elahere :

Is Elahere effective for ovarian cancer? What are the side effects of elahere? How does elahere treat ovarian cancer? Elahere cost? Elahere? Elahere patent? Elahere generic?